相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Lesley A. Smith et al.
BMC CANCER (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Giuseppe Curigliano et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
Antineoplastic Chemotherapy Induced QTc Prolongation
Claudia Bagnes et al.
CURRENT DRUG SAFETY (2010)
Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
Manuela Fiúza
ADVANCES IN THERAPY (2009)
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo et al.
ANNALS OF ONCOLOGY (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Renske Altena et al.
LANCET ONCOLOGY (2009)
The diagnosis and management of cardiovascular disease in cancer patients
Syed Wamique et al.
CURRENT PROBLEMS IN CARDIOLOGY (2008)
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Jose A. Casado et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Detection and monitoring of cardiotoxicity - what does modern cardiology offer?
Ruxandra Jurcut et al.
SUPPORTIVE CARE IN CANCER (2008)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
C. N. Krasner et al.
BRITISH JOURNAL OF CANCER (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval
Elizabeth L. Strevel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trabectedin- A review of its use in the management of soft tissue sarcoma and ovarian cancer
Natalie J. Carter et al.
DRUGS (2007)
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects
Joseph R. Carver et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
L. Zelek et al.
BRITISH JOURNAL OF CANCER (2006)
Cardiotoxicity of cancer therapy
JD Floyd et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Transcriptional signature of ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
N Martínez et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
C Sessa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
DJ Lenihan et al.
BLOOD (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Cardiac dysfunction in the trastuzumab clinical trials experience
A Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: Is there cause for concern?
DL Keefe
ONCOLOGIST (2002)
Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650
EJ Martinez et al.
CHEMISTRY & BIOLOGY (2001)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
G Damia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
AA Gabizon
CANCER INVESTIGATION (2001)
分享论文
